Are Urooncologists Onboard?
Abstract
Lu-PSMA-617 therapy, which has demonstrated survival benefits and favorable safety profiles in metastatic castration-resistant prostate cancer. As evidence expands into earlier disease stages, PSMA radiopharmaceutical therapy is emerging as a key systemic treatment modality. The article emphasizes the importance of multidisciplinary care and the evolving role of nuclear medicine as both a diagnostic and a therapeutic partner. It also highlights current challenges and regional disparities in access, encouraging thoughtful, patient-centered adaptation of theranostic advances.
Fields of Study & Subjects
Surgical Simulation and Training
Global Health and Surgery
Diversity and Career in Medicine
Publication details
- Journal / source
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Volume
- 67
- Issue
- Supplement 2
- Pages
- 3S–4S
- Publication date
- 1 September 2026
- Language
- EN